Targeting non-coding RNAs to overcome cancer therapy resistance

BQ Chen, MP Dragomir, C Yang, Q Li, D Horst… - Signal transduction and …, 2022 - nature.com
It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts,
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Y Yang, S Li, Y Wang, Y Zhao, Q Li - Signal transduction and targeted …, 2022 - nature.com
Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance

X Guo, C Gao, DH Yang, S Li - Drug Resistance Updates, 2023 - Elsevier
Chemotherapy is one of the primary treatments for malignant tumors. However, the acquired
drug resistance hinders clinical efficacy and leads to treatment failure in most patients …

A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma

JL Duan, W Chen, JJ Xie, ML Zhang, RC Nie, H Liang… - Molecular cancer, 2022 - Springer
Abstract Background Circular RNAs (circRNAs) regulate various biological activities and
have been shown to play crucial roles in hepatocellular carcinoma (HCC) progression …

Going circular: history, present, and future of circRNAs in cancer

G Pisignano, DC Michael, TH Visal, R Pirlog… - Oncogene, 2023 - nature.com
To date, thousands of highly abundant and conserved single-stranded RNA molecules
shaped into ring structures (circRNAs) have been identified. CircRNAs are multifunctional …

Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer

H Shen, B Liu, J Xu, B Zhang, Y Wang, L Shi… - Journal of Hematology & …, 2021 - Springer
Background Hepatocellular carcinoma (HCC) is one of the most common malignancies
globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC …

Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance

H Lin, Y Wang, P Wang, F Long, T Wang - Molecular cancer, 2022 - Springer
The resistance of tumor cells to therapy severely impairs the efficacy of treatment, leading to
recurrence and metastasis of various cancers. Clarifying the underlying mechanisms of …

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

X Zhou, X Ao, Z Jia, Y Li, S Kuang, C Du… - Frontiers in …, 2022 - frontiersin.org
Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a
serious, long-term threat to patients' health and life. Systemic chemotherapy remains the first …

Extracellular vesicles in cancer drug resistance: roles, mechanisms, and implications

Q Yang, J Xu, J Gu, H Shi, J Zhang, J Zhang… - Advanced …, 2022 - Wiley Online Library
Extracellular vesicles (EVs) are cell‐derived nanosized vesicles that mediate cell‐to‐cell
communication via transporting bioactive molecules and thus are critically involved in …

Mechanisms of drug resistance in HCC

AD Ladd, S Duarte, I Sahin, A Zarrinpar - Hepatology, 2024 - journals.lww.com
HCC comprises∼ 80% of primary liver cancer. HCC is the only major cancer for which death
rates have not improved over the last 10 years. Most patients are diagnosed with advanced …